Abstract 5494
Background
Oncogenic fibroblast growth factor receptor (FGFR) gene fusions have been described in diverse tumor histology. FGFR inhibitors including erdafitinib have demonstrated promising results in patients whose tumors harbor FGFR gene fusions or mutations. We hereby assessed the frequency of FGFR rearrangements in the Chinese non-small cell lung cancer (NSCLC) population.
Methods
A total of 10,966 NSCLC patients whose tumor specimen and/or circulating cell-free DNA (cfDNA) submitted for genomic profiling by hybridization capture-based targeted next-generation sequencing (NGS) of exons and introns of cancer related genes were retrospectively reviewed. Patients’ clinical characteristics and treatment history were retrieved from the database for further evaluation.
Results
FGFR fusions retaining the intact kinase domain were identified in 0.11% (12/10966) of NSCLC cases examined, including 9 fibroblast growth factor receptor 3 (FGFR3)-transforming acidic coiled-coil containing protein 3 gene (TACC3) fusion-positive cases that was mostly reported in solid tumors, one fibroblast growth factor receptor 2 (FGFR2)-internexin neuronal intermediate filament protein α gene (INA) fusion that was previously reported in gliomas, one novel fibroblast growth factor receptor 4 (FGFR4)-Rap guanine nucleotide exchange factor like 1 gene (RAPGEFL1) fusion case, and one novel fibroblast growth factor receptor 1 (FGFR1) gene fusion involving the 5’UTR of Solute Carrier Family 20 Member 2 gene (SLC20A2) which may possibly drive the overexpression of FGFR1. Concomitant EGFR mutations or EGFR amplification were observed in 6 patients, four of which were previously treated with EGFR tyrosine kinase inhibitors (TKIs), but disease progressed prior to NGS tests. FGFR fusions may arise as resistance mechanism to EGFR TKI therapies in patients who carried founder EGFR alterations. No other known concurrent driver mutations were detected in the remaining 6 cases.
Conclusions
We hereby report a frequency of FGFR fusions of 0.11% in a large Chinses NSCLC population involving known and novel FGFR gene fusion partners including TACC3, INA, RAPGEFL1, and SLC20A2. Oncogenic FGFR fusions may arise as mechanisms of acquired resistance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Geneseeq Technology Inc.
Funding
Has not received any funding.
Disclosure
Q. Ou: Full / Part-time employment, NA: Geneseeq Technology Inc. X. Wu: Leadership role, NA: Geneseeq Technology Inc. X. Wang: Full / Part-time employment, NA: Nanjing Geneseeq Technology Inc. Y.W. Shao: Leadership role, NA: Geneseeq Technology Inc. All other authors have declared no conflicts of interest.
Resources from the same session
3909 - Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing
Presenter: Ying Huang
Session: Poster Display session 1
Resources:
Abstract
3061 - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma
Presenter: Ye Chen
Session: Poster Display session 1
Resources:
Abstract
4735 - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing
Presenter: Xin Wang
Session: Poster Display session 1
Resources:
Abstract
5236 - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
4051 - cRGDfK (cRGD) conjugated Pyropheophor¬bide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing
Presenter: Fengwei Wang
Session: Poster Display session 1
Resources:
Abstract
859 - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.
Presenter: Kevin Doello
Session: Poster Display session 1
Resources:
Abstract
2497 - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Presenter: Jenny Thirlway
Session: Poster Display session 1
Resources:
Abstract
1636 - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells
Presenter: Wen-shan Li
Session: Poster Display session 1
Resources:
Abstract
3443 - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
Presenter: Margarita Yastrebova
Session: Poster Display session 1
Resources:
Abstract
840 - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Presenter: Li Cheng
Session: Poster Display session 1
Resources:
Abstract